Pedro Valencia, VP, asset strategy leadership, oncology, AbbVie, discusses how early data from ABBV-706 shows up to 50% ...

Under the renewed deal, Bayer and Tsinghua University will work to enhance the drug discovery and development process across ...

Final results from the Phase IV PEARL trial show that 66% of patients treated with Ajovy for episodic migraine and more than half of those treated for chronic migraine who responded during the first ...

Under terms of the deal, Kymera will lead early research on novel oral CDK2 degraders for solid tumors, with Gilead assuming ...

A panel of industry leaders emphasize the importance of early engagement with payers, real-world evidence, and value-based ...

Results from the Phase III SUNMO trial show that the Lunsumio and Polivy combination achieved statistically significant ...

In a functioning system, the kind of placebo-controlled vaccine trials that Secretary Kennedy is calling for would never get past an IRB, much less progress to an IND application. Vaccines are being ...

Pedro Valencia, VP, asset strategy leadership, oncology, AbbVie, explains how the company is advancing Temab-A across ...

Early results from the Phase I/II NXTAGE trial show that NXT007 may achieve hemostatic normalization in patients with ...

Approval was based on results from the Phase II TROPION-Lung05 trial, which showed that Datroway demonstrated a strong ...

As such, Novo Nordisk ended its collaboration with Hims & Hers over concerns of illegal mass compounding and deceptive ...

The ADDF’s CFO discusses the areas that foundation is raising money for and how its reacting to the current economic ...